Table 3.

Change from baseline in UPDRS subdomains

Variable (FAS population)	Baseline score (mean ± SD)	Change from baseline at week 12 (marginal mean ± SE)
Subdomains of UPDRS
Mentation
Placebo	0.37 ± 0.52 (N = 63)	−0.04 ± 0.05 (N = 60)
Rasagiline	0.38 ± 0.53 (N = 52)	−0.09 ± 0.06 (N = 52)
Thought disorder
Placebo	0.27 ± 0.48 (N = 63)	−0.04 ± 0.04 (N = 60)
Rasagiline	0.17 ± 0.43 (N = 52)	−0.07 ± 0.05 (N = 52)
Depression
Placebo	1.68 ± 0.74 (N = 63)	−0.28 ± 0.08 (N = 60)
Rasagiline	1.56 ± 0.70 (N = 52)	−0.59 ± 0.09* (N = 52)
Motivation/initiative
Placebo	1.13 ± 0.87 (N = 63)	−0.07 ± 0.08 (N = 60)
Rasagiline	1.06 ± 0.94 (N = 52)	−0.33 ± 0.09 (N = 52)

UPDRS, Unified Parkinson’s Disease Rating Scale; FAS, full-analysis set.

^*Significant difference.